Lipid Matrix Nanoparticles: Pharmacokinetics and Biopharmaceutics

WOS: 000271386300019Lipid matrix nanoparticles, such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), have been sought as a useful alternative for formulating poorly soluble drugs intended for several administration routes, e. g. oral, parenteral and topical. These systems are surfaced by a film of surfactant in an aqueous phase, being therefore physicochemically and thermodynamically stable having a mean particle size below 1 m. The matrix of SLN is solely composed of a pure solid lipid ( melting point above 40 degrees C) whereas NLC is composed of a blend of solid and liquid lipids, which must also be solid at both body and room temperatures. The achievements of SLN and NLC as drug carrier systems are due to several advantages, e. g. incorporation of hydrophobic and hydrophilic drug molecules ( including peptides and proteins), controlled release, protection of chemically labile drugs, fulfil several prerequisites for an optimum colloidal drug carrier. The present review aims to emphasize the special features of lipid matrix nanoparticles, in particular for controlled release purposes. An overview on pharmacokinetic and biopharmaceutic results achieved by different research groups is given and their parameters are analyzed

Nanobiotechnology approaches for targeted delivery of pharmaceutics and cosmetics ingredients

Nanobiotechnology refers to the ability to create and manipulate biological and bio-chemical materials, devices, and systems at atomic and molecular levels. Nano delivery systems hold great potential to overcome some of the obstacles in bio-pharmaceutical production, such as water soluble/insoluble pharmaceutical drugs and cosmetic ingredients, risks of toxicity, increasing bio-active efficacy, specificity, tolerability and its therapeutic index. Within nanoparticulate carriers, polymeric and lipid nanoparticles have risen to the forefront of bio-technology, having diverse applications in several fields of pharmaceuticals for oral, topical, ocular and intravenous administration, as well as in dermo-cosmetic products.info:eu-repo/semantics/publishedVersio

Optimization of Cationic SLN for Gene Delivery

Cationic SLN formulations were developed and optimized in terms of cationic lipid/surfactant ratio and production parameters. [...

Modified rose bengal assay for surface hydrophobicity evaluation of cationic solid lipid nanoparticles (cSLN)

Surface hydrophobicity of nanocarriers influences protein binding and subsequently fate of nanoparticles in blood circulation. Therefore, characterization of surface hydrophobicity of nanocarriers provides important preclinical information. Here, a modified classical adsorption method for the needs of characterization of cationic solid lipid nanoparticles (cSLN) was developed. We have identified possible method limitations that should be considered when performing the analysis, i.e. the problems associated with particle separation from the dispersion and their own absorbance in visible spectrum. We propose two modified methods for performing the assay overcoming the stated limitations. We also discuss here evaluation by different approaches (calculation of binding constants or partitioning quotient) and their suitability for the prepared cSLN formulation. Overall, we confirmed that our modified adsorption method can provide useful information about surface properties of (cationic) SLN, however, performing and evaluation of the assay need special attention in order to obtain the desired results.info:eu-repo/semantics/publishedVersio

Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies

Cationic solid lipid nanoparticles (cSLN) are promising lipid nanocarriers for intracellular gene delivery based on well-known and widely accepted materials. cSLN containing single-chained cationic lipid cetyltrimethylammonium bromide were produced by high pressure homogenization and characterized in terms of(a) particle size distribution by photon correlation spectroscopy (PCS) and laser diffractometry (LD), (b) thermal behaviour using differential scanning calorimetry (DSC) and (c) the presence of various polymorphic phases was confirmed by X-ray diffraction (WAXD). SLN composed of Imwitor 900PTM (IMW) showed different pDNA stability and binding capacity in comparison to those of Compritol 888 ATOTM (COM). IMW-SLN, having z-ave = 138–157 nm and d(0.5) = 0.15–0.158 m could maintain this size for 14 days at room temperature. COM-SLN had z-ave = 334 nm and d(0.5) = 0.42 m on the day of production and could maintain similar size during 90 days. IMW-SLN revealed improved pDNA binding capacity. We attempted to explain these differences by differentinteractions between the solid lipid and the tested cationic lipid.info:eu-repo/semantics/publishedVersio